Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of donanemab for Alzheimer's disease
ChiCTR2600132189Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donanemab in Alzheimer's disease (AD), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment at Week 68, Alzheimer's Disease Composite Score at Week 68 and 2 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2600132189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132189.